DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Alteration in Timing of Plerixafor Administration

Information source: Emory University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Autologous Transplantation

Intervention: Plerixafor (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: Emory University

Official(s) and/or principal investigator(s):
R. Donald Harvey, PharmD, FCCP, Principal Investigator, Affiliation: Emory University Winship Cancer Institute

Summary

Typically, the collection of blood cells for autologous stem cell transplant is done after the drugs granulocyte colony-stimulating factor (G-CSF) and plerixafor have been given to activate the bone marrow stem cells to produce a certain type of blood cell, called CD34+ cells. Currently, plerixafor is given in the evening, about 11 hours before apheresis (removal of blood) begins the following morning. The purpose of this study is to test whether plerixafor can instead be given 17 hours before apheresis. This timing would be more convenient since plerixafor would be given during normal clinic hours, and so patients would be within a clinic environment if any side effects develop. The study will look for the activation of CD34+ cells in patients who receive plerixafor 17 hours before apheresis. We will follow the number of patients that achieve the target numbers of CD34+ cells, and the total number of CD34+ cells collected. These will be compared to the numbers in previous studies giving plerixafor 11 hours before apheresis. We will also assess the safety of giving plerixafor 17 hours before apheresis.

Clinical Details

Official title: WCI1680-09: Evaluation of Alterations in Time of Administration of Plerixafor (Mozobil ®, AMD3100) in Combination With G-CSF on Safety and CD34+ Cell Mobilization

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Number of Patients Who Collected ≥ 6 x 10^6 CD34+ Cells by Day 5 (4 Apheresis Sessions) With Plerixafor Administration at 1500.

Secondary outcome: Number of Patients Who on Day 1 Collected > 10 x 10^6 CD34+ Cells/kg Following Plerixafor Dosing at 1500 Hrs

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Age 18-70 years 2. MM patients in first or second complete or partial remission 3. ECOG performance status of 0 or 1 4. Up to 3 prior treatment regimens 5. Meet all eligibility requirements for autologous transplant 6. Adequate marrow function defined as WBC >3,000; ANC >1,500/mm3 ; Platelets >75,000/mm3 7. Adequate renal function defined as creatinine clearance > 30 mL/min by Cockcroft-Gault 8. Adequate liver function defined as AST/ALT/Bilirubin < 2 times upper limit of normal 9. Able to provide informed consent 10. Women not pregnant and agree to use contraception Exclusion Criteria: 1. High risk co-morbidities for acute treatment complications (e. g., symptomatic coronary artery disease) 2. Brain metastases or carcinomatous meningitis 3. Previous treatment with high dose chemotherapy and autologous transplant. 4. Previous attempt to collect B-HPCs following mobilization with growth factors alone, growth factors and chemotherapy, or plerixafor and growth factors. 5. Acute infection or unexplained fever >38°C 6. Weight > 175% of ideal body weight as defined by the Devine equation. 7. Experimental therapy within 4 weeks 8. Cytokine administration in the previous 14 days

Locations and Contacts

Emory University Winship Cancer Institute, Atlanta, Georgia 30322, United States
Additional Information

Starting date: June 2010
Last updated: November 19, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017